William Blair Investment Management LLC Has $24.39 Million Holdings in Treace Medical Concepts, Inc. $TMCI

William Blair Investment Management LLC raised its holdings in Treace Medical Concepts, Inc. (NASDAQ:TMCI) by 17.2% during the third quarter, HoldingsChannel.com reports. The fund owned 3,634,381 shares of the company’s stock after purchasing an additional 534,486 shares during the period. William Blair Investment Management LLC owned approximately 0.06% of Treace Medical Concepts worth $24,387,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of TMCI. Armistice Capital LLC lifted its holdings in shares of Treace Medical Concepts by 0.8% in the second quarter. Armistice Capital LLC now owns 6,260,000 shares of the company’s stock worth $36,809,000 after acquiring an additional 49,000 shares during the last quarter. Gagnon Securities LLC lifted its stake in Treace Medical Concepts by 0.4% in the 3rd quarter. Gagnon Securities LLC now owns 2,258,238 shares of the company’s stock valued at $15,153,000 after purchasing an additional 8,090 shares during the last quarter. Geode Capital Management LLC boosted its position in Treace Medical Concepts by 3.0% in the second quarter. Geode Capital Management LLC now owns 1,119,581 shares of the company’s stock valued at $6,584,000 after buying an additional 32,438 shares in the last quarter. Gagnon Advisors LLC grew its stake in shares of Treace Medical Concepts by 16.6% during the third quarter. Gagnon Advisors LLC now owns 968,464 shares of the company’s stock worth $6,498,000 after buying an additional 138,194 shares during the last quarter. Finally, First Eagle Investment Management LLC grew its stake in shares of Treace Medical Concepts by 82.0% during the second quarter. First Eagle Investment Management LLC now owns 908,029 shares of the company’s stock worth $5,339,000 after buying an additional 409,105 shares during the last quarter. Institutional investors and hedge funds own 84.08% of the company’s stock.

Analyst Upgrades and Downgrades

TMCI has been the subject of a number of research reports. Lake Street Capital dropped their price target on Treace Medical Concepts from $7.50 to $7.00 and set a “buy” rating for the company in a research note on Monday. UBS Group dropped their target price on Treace Medical Concepts from $6.50 to $5.85 and set a “neutral” rating for the company in a research report on Friday, November 7th. Truist Financial reduced their price target on Treace Medical Concepts from $4.00 to $3.00 and set a “hold” rating on the stock in a report on Thursday, December 18th. Wall Street Zen lowered shares of Treace Medical Concepts from a “hold” rating to a “sell” rating in a report on Tuesday. Finally, Stifel Nicolaus cut their target price on shares of Treace Medical Concepts from $5.00 to $3.00 and set a “hold” rating on the stock in a research report on Wednesday, January 7th. One investment analyst has rated the stock with a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Reduce” and an average price target of $4.77.

Treace Medical Concepts Price Performance

Shares of TMCI opened at $1.66 on Tuesday. The business has a 50-day moving average of $2.34 and a 200-day moving average of $4.35. The company has a debt-to-equity ratio of 0.60, a current ratio of 3.37 and a quick ratio of 2.36. The company has a market capitalization of $105.77 million, a price-to-earnings ratio of -1.77 and a beta of 0.74. Treace Medical Concepts, Inc. has a 1 year low of $1.58 and a 1 year high of $9.56.

Treace Medical Concepts (NASDAQ:TMCI) last released its earnings results on Friday, February 27th. The company reported ($0.15) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.15). The business had revenue of $62.52 million during the quarter, compared to the consensus estimate of $61.76 million. Treace Medical Concepts had a negative net margin of 27.74% and a negative return on equity of 58.37%. As a group, equities research analysts anticipate that Treace Medical Concepts, Inc. will post -0.92 earnings per share for the current year.

Treace Medical Concepts Company Profile

Treace Medical Concepts, Inc is a medical technology company specializing in the development and commercialization of innovative surgical solutions for foot and ankle conditions. The company’s flagship product, the Lapiplasty 3D Bunion Correction System, addresses the underlying joint instability that causes bunion deformity through a patented, multi-plane correction approach. The system combines proprietary instrumentation, fixation plates, and a comprehensive surgical protocol designed to improve patient outcomes and reduce recurrence rates.

The Lapiplasty System has received clearance from the U.S.